Clinical trials: Cholangiocarcinomas
HCC - Hepatocellular Carcinoma, Cholangiocarcinoma
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively.
- Conditions
- HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT07106827
- Testing
- GV20-0251
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Combined Hepatocellular-cholangiocarcinoma, Liver Neoplasms
Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Title: A Study of Cadonilimab Combined with Capecitabine After Surgery for Mixed Type Liver Cancer This is a phase II clinical trial.
- Trial name
- NCT07243951
- Testing
- Cadonilimab, Capecitabine
- Volunteers
- 75 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Interventional AI-Human Collaboration for Liver Tumor Diagnosis
Recent advances in artificial intelligence (AI), particularly deep learning technology, have transformed medical imaging analysis.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
- Trial name
- NCT07153783
- Testing
- AI-human collaboration for CE-CTs diagnosis
- Where
- China
- Volunteers
- 10,333 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Gynecologic Cancer, Colorectal Cancer
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05194735
- Testing
- Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
This pilot trial studies how well single photon emission computed tomography (SPECT)/computed tomography (CT) with technetium Tc-99m sulfur colloid works in measuring liver function in patients with liver cancer that has or has…
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer
- Trial name
- NCT02881554
- Testing
- Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Intrahepatic Cholangiocarcinoma
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment).
- Trial name
- NCT05328167
- Testing
- Perflutren Protein-Type A Microspheres, Contrast-Enhanced Ultrasound
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Thomas Jefferson University
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
This is an Open-label, Phase 1b/2 Study of the Pressure-Enabled Hepatic Artery Infusion (HAI) of SD-101, a TLR9 agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Hepatocellular Carcinoma (HCC)…
- Trial name
- NCT05220722
- Testing
- SD-101, Pembrolizumab, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- TriSalus Life Sciences, Inc.
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer
- Trial name
- NCT03144661
- Testing
- INCB062079
- Where
- 6 sites in United States, Belgium
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy
A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST
This project aims to conduct a prospective, multicenter, randomized controlled clinical trial. The study plans to enroll 270 patients with locally advanced iCCA who have successfully undergone GOLP conversion therapy.
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy, TDTP-RECIST, GOLP Regimen
- Trial name
- NCT07208526
- Testing
- GOLP regimen, Surgery, TDTP-RECIST
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Shanghai Zhongshan Hospital
Adenocarcinoma Metastatic, Biliary Tract Cancer
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial
- Conditions
- Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract, Adenocarinoma Locally Advanced
- Trial name
- NIFE (NCT03044587)
- Testing
- Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B)
- Where
- Germany
- Volunteers
- 93 people
- Sponsor
- AIO-Studien-gGmbH
Advanced Cancer, Anal Carcinoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- Conditions
- Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer
- Trial name
- NCT02628067
- Testing
- pembrolizumab
- Volunteers
- 1,609 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenocarcinoma, Neuroendocrine Tumors
EchoTip AcuCore Post-Market Clinical Study
The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the…
- Conditions
- Adenocarcinoma, Neuroendocrine Tumors, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT06358001
- Testing
- EchoTip AcuCore
- Where
- 8 sites in United States
- Volunteers
- 183 people
- Sponsor
- Cook Research Incorporated
Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
Biliary tract carcinoma (BTC), including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, ranks sixth in incidence among gastrointestinal malignancies and tenth in cancer-related mortality…
- Conditions
- Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma
- Trial name
- NCT07176962
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Yingbin Liu, MD, PhD, FACS
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for…
- Trial name
- NCT03929666
- Testing
- ZW25 (Zanidatamab), Capecitabine, Cisplatin
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 74 people
- Sponsor
- Jazz Pharmaceuticals
Gastrointestinal Carcinoma, Pancreatic Cancer
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Background: Gastrointestinal (GI) cancer affects the organs (such as the stomach, large and small intestine, pancreas, colon, liver, and biliary system) of the digestive tract.
- Conditions
- Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma
- Trial name
- NCT06690281
- Testing
- KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Cholangiocarcinoma (Part 1)
A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping
This is a multi-center, real-world study aiming to evaluate the efficacy and safety of precision treatment for advanced cholangiocarcinoma (CCA) with different molecular subtypes.
- Trial name
- NCT07164703
- Testing
- Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Mao-Lin Yan
Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
This trial is to evaluate the palliative effects of colchicine on primary hepatic malignancy using the Department of Health R.O.C. approved doses and methods of administration.
- Conditions
- Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma; With Hepatocellular Carcinoma, Hepatocellular Carcinoma Stage IV
- Trial name
- NCT04264260
- Testing
- Colchicine Tablets
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics